Compare Neurocrine Biosciences Inc (NBIX) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Atlassian Corporation PLC — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Atlassian Corporation PLC trades at $90.49 (market cap $23.67B). The key difference: Atlassian Corporation PLC is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Atlassian Corporation PLC nearer its low. Which is the better fit depends on your goals.
| NBIX | TEAM | |
|---|---|---|
Market Cap | $17.40B | $23.67B |
Sector | Health | Technology |
52-Week High | $180.55 | $203.00 |
52-Week Low | $123.10 | $57.15 |
Enterprise Value | $16.49B | $23.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Atlassian (TEAM) trades at $90.60, down 2.88% on the day, with a bullish technical signal from moving averages and strong analyst support (67% buy ratings). The company shows accelerating revenue growth, reaching $5.22B in 2025, and has beaten earnings estimates for three consecutive quarters. Recent news highlights AI-driven product enhancements and enterprise adoption momentum, with the Service Collection surpassing $1B in annual recurring revenue.
TEAM presents a growth investment case with a consensus price target of $114.54 (26% upside), supported by cloud momentum and AI integration. However, persistent net losses (-$256.69M in 2025) and high valuation multiples (P/S 3.96, P/B 26.93) pose risks amid competitive pressures and macroeconomic sensitivity in software spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
